AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia.
Researchers at the RIKEN Center for Brain Science identified a new protein that might make the connection between amyloid plaques and tau in Alzheimer’s patients.
Global Blood Therapeutics reported new data from the company’s Phase III HOPE trial of voxelotor in sickle cell disease (SCD).
After hitting the American College of Rheumatology 20 percent (ACR20) improvement mark in two Phase III trials, Janssen Pharmaceutical is planning to seek regulatory approval for Tremfya in adult patients with active moderate to severe psoriatic arthritis.
A smartphone-based relaxation app could help migraine sufferers reduce the number of headaches they get each month, a small study suggests.
Enanta Pharmaceuticals Inc.’s treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.
EpiPens and other autoinjectors filled with epinephrine to treat severe allergic reactions may still be potent enough to work many months past their labeled expiration date, according to a study that concludes patients might need expensive refills less often.
Genentech announced positive topline results from the Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug MMF in patients with pemphigus vulgaris.
Shares of Texas-based Savara Inc. were down more than 72 percent after the company announced that the experimental autoimmune alveolar pulmonary proteinosis (aPAP) treatment Molgradex failed to hit the primary endpoint in a late-stage study.
A research review evaluates how well various measures work to reduce consumption of sugary sodas and other sweetened drinks.
